FDA Approves First Gene Therapy for Genetic Hearing

How Does the New Gene Therapy Restore Hearing?

Otoferlin is a protein essential for transmitting sound signals from the cochlea's sensory hair cells to the auditory nerve. Children born with two faulty copies of the OTOF gene cannot produce functional otoferlin, leaving them with profound congenital deafness despite having structurally intact hair cells. The newly approved Regeneron therapy uses an adeno-associated virus (AAV) vector to deliver a working copy of the gene directly into the inner ear during a brief surgical procedure.

Once delivered, the genetic instructions allow hair cells to begin producing functional otoferlin protein, restoring the synaptic connection to the auditory nerve. Clinical trial results reported by Regeneron showed meaningful hearing recovery in treated children, many of whom went from profound deafness to being able to perceive conversational speech within months of treatment. Because the therapy targets a single, well-characterized molecular defect, it represents a proof-of-concept for treating other genetic forms of hearing loss.

Who Is Eligible for This Hearing Loss Treatment?

Genetic testing is required to confirm that a child's hearing loss is caused by mutations in both copies of the OTOF gene. This form of deafness, sometimes called DFNB9, accounts for an estimated 1 to 8 percent of congenital genetic hearing loss cases worldwide. Identification typically occurs through newborn hearing screening followed by genetic confirmation, which is increasingly part of standard pediatric audiology workups.

Patients who do not have OTOF mutations — including those with hearing loss from other genetic causes, infections, or noise exposure — will not benefit from this specific therapy. However, the FDA approval signals to the broader research community that gene therapy for inherited deafness is clinically viable, and several other programs targeting genes such as GJB2 (connexin 26) and STRC are advancing through earlier-stage trials.

What Are the Risks and Long-Term Considerations?

The intracochlear injection requires a specialized surgical procedure performed by an otologist, with risks similar to cochlear implant surgery, including temporary inflammation, dizziness, and rare complications such as infection. Because the AAV vector is delivered locally to the inner ear, systemic immune reactions appear to be limited compared with intravenous gene therapies.

Long-term durability remains an active area of follow-up. Early data suggests sustained otoferlin expression and stable hearing improvement over multiple years in initial trial participants, but post-marketing surveillance will be essential to confirm that benefits persist into adolescence and adulthood. Families considering treatment should discuss with their care team how outcomes compare with cochlear implants, which remain a well-established standard of care for severe-to-profound hearing loss.